Amanita muscaria (also known as fly agaric) is a type of mushroom with hallucinogenic properties. It is also not listed on any schedule of the
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment
First Numinus Network™ partner enters into agreement Recent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned
The research conducted at Cedar Clinical Research in Draper is part of the first ever phase 3 program of psilocybin therapy, and the largest of
KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing intravenous-infused
Healthy subjects have been dosed with Filament’s botanical psilocybin and psilocin drug candidates VANCOUVER, BC, May 30, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF)
Vancouver, British Columbia–(Newsfile Corp. – May 31, 2023) – Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (“the Company” or “Cognetivity”), a leading provider
Albert Labs has received preliminary acceptance of 35 novel inventive claims as part of its published International PCT Patent Application (No. PCT/CA2022/051281). The Company’s proprietary
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee on Friday voted 6-0 in favor of fully approving Eisai and Biogen’s Alzheimer’s drug Leqembi
The FDA said it worked with pharma companies to prevent more than 200 drug shortages last year. However, the regulator still grappled with a steady